Literature DB >> 28616774

[Molecular component-resolved allergy diagnostics in ENT].

L Klimek1, S Becker2.   

Abstract

Molecular component-resolved diagnostics (CRD) are, in addition to its research applications, being increasingly used in daily allergological routine. CRD offers improved diagnostic accuracy via a better understanding of the underlying allergen causing symptoms and helps to distinguish between true sensitization and cross reactions in polysensitized patients, thereby providing an approach for individual personalized therapy. Particularly in food allergies and anaphylaxis, CRD can stratify risks for the recurrence of reactions and their severity. The education and extended vocational training of clinical allergologists has to keep pace with the tremendous increase of knowledge in the field of molecular allergology.

Entities:  

Keywords:  Allergen components; Allergens; Allergic rhinitis; Cross reactions; Molecular allergology

Mesh:

Substances:

Year:  2017        PMID: 28616774     DOI: 10.1007/s00106-017-0372-6

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  33 in total

Review 1.  Determinants of allergenicity.

Authors:  Claudia Traidl-Hoffmann; Thilo Jakob; Heidrun Behrendt
Journal:  J Allergy Clin Immunol       Date:  2009-01-18       Impact factor: 10.793

2.  Allergen nomenclature.

Authors:  D G Marsh; L Goodfriend; T P King; H Lowenstein; T A Platts-Mills
Journal:  Bull World Health Organ       Date:  1986       Impact factor: 9.408

3.  Component-resolved diagnosis (CRD) of type I allergy with recombinant grass and tree pollen allergens by skin testing.

Authors:  S Heiss; V Mahler; R Steiner; S Spitzauer; C Schweiger; D Kraft; R Valenta
Journal:  J Invest Dermatol       Date:  1999-11       Impact factor: 8.551

4.  [Individualized, personalized and stratified medicine: a challenge for allergology in ENT?].

Authors:  Adam M Chaker; L Klimek
Journal:  HNO       Date:  2015-05       Impact factor: 1.284

5.  [Recombinant allergens. For routine use or still only science?].

Authors:  P Schmid-Grendelmeier
Journal:  Hautarzt       Date:  2010-11       Impact factor: 0.751

6.  Recombinant marker allergens in diagnosis of patients with allergic rhinoconjunctivitis to tree and grass pollens.

Authors:  Martin Canis; Moritz Gröger; Sven Becker; Christine Klemens; Matthias F Kramer
Journal:  Am J Rhinol Allergy       Date:  2011 Jan-Feb       Impact factor: 2.467

7.  Vaccination with genetically engineered allergens prevents progression of allergic disease.

Authors:  V Niederberger; F Horak; S Vrtala; S Spitzauer; M-T Krauth; P Valent; J Reisinger; M Pelzmann; B Hayek; M Kronqvist; G Gafvelin; H Grönlund; A Purohit; R Suck; H Fiebig; O Cromwell; G Pauli; M van Hage-Hamsten; R Valenta
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

8.  Clinical usefulness of microarray-based IgE detection in children with suspected food allergy.

Authors:  H Ott; J M Baron; R Heise; C Ocklenburg; S Stanzel; H-F Merk; B Niggemann; K Beyer
Journal:  Allergy       Date:  2008-11       Impact factor: 13.146

9.  Real-Life Study for the Diagnosis of House Dust Mite Allergy - The Value of Recombinant Allergen-Based IgE Serology.

Authors:  Sven Becker; Thomas Schlederer; Matthias F Kramer; Mareike Haack; Susanne Vrtala; Yvonne Resch; Christian Lupinek; Rudolf Valenta; Moritz Gröger
Journal:  Int Arch Allergy Immunol       Date:  2016-08-10       Impact factor: 2.749

10.  Molecular composition and biological activity of commercial birch pollen allergen extracts.

Authors:  M Focke; K Marth; R Valenta
Journal:  Eur J Clin Invest       Date:  2009-05       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.